Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 15/20 | 0.60 |
| ▸ | CALCR | P30988 | 3/20 | 0.59 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.58 |
| ▸ | GCGR | P47871 | 1/20 | 0.55 |
| ▸ | GIPR | P48546 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29973140 | 0.98 | CALCR (0.61) | GLP1RCALCRPTH1R | |
| SCHEMBL31376429 | 0.98 | PTH1R (0.60) | GLP1RCALCRPTH1RGCGRGIPR | |
| SCHEMBL29973297 | 0.97 | GLP1R (0.62) | GLP1R | |
| SCHEMBL29973649 | 0.93 | GLP1R (0.61) | GLP1RPTH1RGCGRGIPR | |
| SCHEMBL29973471 | 0.92 | GLP1R (0.60) | GLP1R | |
| SCHEMBL29921851 | 0.91 | PTH1R (0.65) | GLP1RPTH1RGCGRGIPR | |
| SCHEMBL30524411 | 0.90 | GLP1R (0.59) | GLP1RGCGRGIPR | |
| SCHEMBL29720268 | 0.90 | CALCR (0.59) | GLP1RCALCRPTH1R | |
| SCHEMBL29973282 | 0.89 | EDNRA (0.56) | GLP1R | |
| SCHEMBL31574195 | 0.89 | GLP1R (0.63) | GLP1RCALCRPTH1RGCGRGIPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137691-A1 | WB3 FOR ANESTHESIA AND TREATING PAIN | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260109760-A1 | NEUTRALIZING ANTIBODIES TO HUMAN ENDOTHELIN | FATHER FLANAGANS BOYS HOME DOING BUSINESS AS BOYS TOWN NATIONAL RES HOSPITAL (US) | 2026-04-23 | — | — | US | disclosed |
| US-12577300-B2 | Neutralizing antibodies to human endothelin | Father Flanagan's Boys' Home Business (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260060221-A1 | METHOD FOR PRODUCING NONHUMAN PRIMATE ANIMAL MODEL OF CEREBRAL INFARCTION AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CEREBRAL INFARCTION | ASTELLAS PHARMA INC. (JP) | 2026-03-05 | — | — | US | disclosed |
| US-20260021061-A1 | ARIADNE AND ANALOGS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROMUSCLAR DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2026-01-22 | — | — | US | disclosed |
| US-20250353808-A1 | 5-METHOXYMETHYL AND 5-HYDROXYMETHYL PHENETHYLAMINES | 2A BIOSCIENCES, INC. | 2025-11-20 | — | — | US | disclosed |
| US-12458624-B2 | Deuterium-enriched substituted phenoxyphenyl acetic acids and acylsulfonamides | DHANOA DALJIT SINGH (US) | 2025-11-04 | — | — | US | disclosed |
| WO-2025137511-A1 | INTEGRATED AND ITERATIVE METHODS FOR DESIGNING, IDENTIFYING AND OPTIMIZING LASSO PEPTIDES | LASSOGEN, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| EP-4548757-A1 | METHOD FOR PRODUCING NON-HUMAN PRIMATE MODEL OF CEREBRAL INFARCTION AND PHARMACEUTICAL COMPOSITION FOR TREATING CEREBRAL INFARCTION | Astellas Pharma, Inc. (JP) | 2025-05-07 | — | — | EP | disclosed |
| US-12240816-B2 | Deuterated compounds and uses thereof | ALDEYRA THERAPEUTICS, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| WO-2023192853-A2 | LASSO PEPTIDES AS ENDOTHELIN B RECEPTOR ANTAGONISTS | LASSOGEN, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| EP-4046995-B1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20230174491-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | ALDEYRA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230039319-A1 | DEUTERIUM-ENRICHED SUBSTITUTED PHENOXYPHENYL ACETIC ACIDS AND ACYLSULFONAMIDES | DHANOA DALJIT SINGH (US) | 2023-02-09 | — | — | US | disclosed |
| US-11459300-B2 | Deuterated compounds and uses thereof | ALDEYRA THERAPEUTICS, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| EP-4046995-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | Sunovion Pharmaceuticals Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| EP-3256466-B9 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC (US) | 2022-07-27 | — | — | EP | disclosed |
| US-20220195034-A1 | NEUTRALIZING ANTIBODIES TO HUMAN ENDOTHELIN | FATHER FLANAGAN'S BOYS' HOME DOING BUSINESS AS BOYS TOWN NATIONAL RESEARCH HOSPITAL | 2022-06-23 | — | — | US | disclosed |
| US-20220185799-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2022-06-16 | — | — | US | disclosed |
| EP-3256466-B1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC (US) | 2022-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039319-A1 | DEUTERIUM-ENRICHED SUBSTITUTED PHENOXYPHENYL ACETIC ACIDS AND ACYLSULFONAMIDES | AGTR2, AGTR1, EDNRA | GLP1R 108/4885CALCR 1207/4885PTH1R 493/4885 |
| US-20260060221-A1 | METHOD FOR PRODUCING NONHUMAN PRIMATE ANIMAL MODEL OF CEREBRAL INFARCTION AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CEREBRAL INFARCTION | FABP7, NES, VEGFA | GLP1R 1723/4885CALCR 1156/4885PTH1R 2984/4885 |
| US-20260109760-A1 | NEUTRALIZING ANTIBODIES TO HUMAN ENDOTHELIN | ETV1, CDR2, IGLV6-57 | GLP1R 2059/4885CALCR 448/4885PTH1R 59/4885 |
| US-12577300-B2 | Neutralizing antibodies to human endothelin | IGLV6-57, ETV1, VEGFA | GLP1R 1997/4885CALCR 602/4885PTH1R 78/4885 |
| US-20260137691-A1 | WB3 FOR ANESTHESIA AND TREATING PAIN | WNT3, TRPV3, ADRB3 | GLP1R 3066/4885CALCR 1169/4885PTH1R 1547/4885 |
| US-20250353808-A1 | 5-METHOXYMETHYL AND 5-HYDROXYMETHYL PHENETHYLAMINES | HTR5A, PNMT, HTR6 | GLP1R 1324/4885CALCR 2238/4885PTH1R 3248/4885 |
| US-20220185799-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | CNR1, HCRTR1, CNR2 | GLP1R 3109/4885CALCR 3640/4885PTH1R 4349/4885 |
| US-20230174491-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | ALDH1A2, SSB, DBH | GLP1R 3683/4885CALCR 4543/4885PTH1R 3498/4885 |
| US-12240816-B2 | Deuterated compounds and uses thereof | ALDH1A2, SSB, DBH | GLP1R 3683/4885CALCR 4543/4885PTH1R 3498/4885 |
| US-12458624-B2 | Deuterium-enriched substituted phenoxyphenyl acetic acids and acylsulfonamides | AGTR2, AGTR1, EDNRA | GLP1R 108/4885CALCR 1207/4885PTH1R 493/4885 |
| US-11459300-B2 | Deuterated compounds and uses thereof | ALDH1A2, SSB, DBH | GLP1R 3683/4885CALCR 4543/4885PTH1R 3498/4885 |
| US-20260021061-A1 | ARIADNE AND ANALOGS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROMUSCLAR DISORDERS | ATXN2, HCRTR2, CDR2 | GLP1R 3215/4885CALCR 488/4885PTH1R 3833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.